Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.
A 66-year-old Japanese woman was referred to us because of severe anemia and fever and presented at our hospital. She was eventually diagnosed as having acute myeloblastic leukemia (AML; M0) with non-Hodgkin lymphoma (NHL). We investigated the therapeutic efficacy of L-asparaginase (L-Asp), vincristine and prednisolone for both her AML and NHL. Asparagine synthetase (AS) activity in her AML blast cells was undetectable. A lymph node biopsy specimen revealed NHL of the marginal zone B cell type. Complete remission (CR) of AML and NHL was achieved. CR of the AML lasted for 18 months without further consolidation therapy. We conclude that L-Asp can be an effective drug for the treatment of AML in which blasts are negative for AS.
Horikoshi
Akira
A
Department of Internal Medicine, Nihon University Nerima Hikarigaoka Hospital, Tokyo, Japan. akhorik@med.nihon-u.ac.jp
Takei
Kazuhiro
K
Iriyama
Noriyoshi
N
Uenogawa
Kumi
K
Ishizuka
Hikaru
H
Shiraiwa
Hidetaka
H
Hosokawa
Yoshifumi
Y
Sawada
Shigemasa
S
Kitoh
Toshiyuki
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use*; D001217:Aspartate-Ammonia Ligase / Q000378:metabolism; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use*; D012074:Remission Induction; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D011239:Prednisolone; D001215:Asparaginase; D001217:Aspartate-Ammonia Ligase